BioLife Solutions' (BLFS) Buy Rating Reaffirmed at HC Wainwright

BioLife Solutions (NASDAQ:BLFS - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $30.00 target price on the medical equipment provider's stock. HC Wainwright's target price suggests a potential upside of 27.17% from the company's previous close. HC Wainwright also issued estimates for BioLife Solutions' Q2 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.00 EPS and FY2026 earnings at $0.03 EPS.

Separately, StockNews.com cut shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.17.

BioLife Solutions Stock Up 7.3%

Shares of NASDAQ:BLFS traded up $1.60 on Tuesday, reaching $23.59. The company had a trading volume of 745,687 shares, compared to its average volume of 384,237. The stock has a market capitalization of $1.12 billion, a P/E ratio of -22.25 and a beta of 2.01. The stock has a 50-day moving average price of $23.52 and a 200 day moving average price of $25.29. BioLife Solutions has a twelve month low of $18.70 and a twelve month high of $29.55. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $23.94 million for the quarter, compared to the consensus estimate of $22.22 million. On average, equities analysts expect that BioLife Solutions will post -0.3 EPS for the current year.

Insider Buying and Selling

In other news, insider Sarah Aebersold sold 5,771 shares of the company's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $130,770.86. Following the completion of the transaction, the insider now owns 80,094 shares of the company's stock, valued at approximately $1,814,930.04. This represents a 6.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Todd Berard sold 8,902 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $201,719.32. Following the completion of the sale, the chief marketing officer now owns 135,956 shares of the company's stock, valued at approximately $3,080,762.96. The trade was a 6.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,696 shares of company stock valued at $1,665,094. 2.20% of the stock is owned by company insiders.

Institutional Trading of BioLife Solutions

Several institutional investors have recently modified their holdings of the company. Proficio Capital Partners LLC bought a new position in BioLife Solutions in the fourth quarter worth $638,000. Alliancebernstein L.P. raised its stake in shares of BioLife Solutions by 11.9% in the 4th quarter. Alliancebernstein L.P. now owns 37,351 shares of the medical equipment provider's stock valued at $970,000 after buying an additional 3,967 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of BioLife Solutions by 18.6% during the 4th quarter. Envestnet Asset Management Inc. now owns 198,695 shares of the medical equipment provider's stock worth $5,158,000 after acquiring an additional 31,167 shares during the period. Victory Capital Management Inc. boosted its position in shares of BioLife Solutions by 422.2% during the 4th quarter. Victory Capital Management Inc. now owns 218,962 shares of the medical equipment provider's stock valued at $5,684,000 after acquiring an additional 177,028 shares in the last quarter. Finally, D.A. Davidson & CO. increased its stake in BioLife Solutions by 1.3% in the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock valued at $1,069,000 after acquiring an additional 519 shares during the period. Institutional investors and hedge funds own 93.24% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.